Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEEOX vs SOX in Stage IIIB/IIIC Gastric Cancer
NCT02338518Phase 3Unknown
- Sponsor
- Jinling Hospital
- Start
- Jan 2015
- Primary completion
- May 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of etoposide, epirubicin in gastric cancer (GC), sponsored by Jinling Hospital. Status: unknown.
02
Drugs
etoposideepirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02338518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338518.